Try our mobile app

General information

Country: UNITED STATES

Sector: Drug Manufacturers — General

Categories: @vaccine-makers   

Merck & Co., Inc. is a global health care company that delivers health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products, which it markets directly and through its joint ventures. The Company has operations in pharmaceutical, animal health, and consumer care.
Website: merck.com


  • Pretty weak financial results growth rate 1.8% (average between last period year over year growth for revenue and EBITDA), there is slowdown compared to average historical growth rates (14.2%)
  • Dividend yield for the last twelve months 4.0%
  • Free cash flow yield 1.5% (LTM)
  • Share price is 10.2% higher than minimum and 39.1% lower than maximum for the last 3 years
  • The company is undervalued by EV / LTM EBITDA multiple compared to target level (9.3x vs
    )
  • Fundamental value created in LTM (estimate)
  • For the last 3 months insiders sold company shares on $0.4 mln (0.000% of cap.)

Key Financials (Download financials)

Ticker: MRK
Share price, USD:  (-0.6%)81
year average price 96.60  


year start price 125.77 2024-07-19

max close price 127.78 2024-07-29

min close price 73.47 2025-05-14

current price 80.99 2025-07-18
Common stocks: 2 528 810 012

Dividend Yield:  4.0%
FCF Yield LTM: 1.5%
EV / LTM EBITDA: 9.3x
EV / EBITDA annualized: 8.3x
Last revenue growth (y/y):  -1.6%
Last growth of EBITDA (y/y):  +5.2%
Historical revenue growth:  +6.4%
Historical growth of EBITDA:  +22.0%
Target EV / EBITDA (hist percentile):
Fundamental value created in LTM:
EV / LTM EBITDA mutiple calculation
Market Cap ($m): 204 834
Net Debt ($m): 25 681
EV (Enterprise Value): 230 515
EBITDA LTM ($m): 24 783
EV / LTM EBITDA: 9.3x
Price to Book: 4.6x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / EBITDA

Potential dynamics

News


2025-07-17seekingalpha.com

Merck & Co., Inc. (MRK) Presents at HIV Investor Event Transcript

2025-07-16seekingalpha.com

Why Merck Is A Better Dividend Stock Than Gilead Sciences

2025-07-15zacks.com

Merck (MRK) Falls More Steeply Than Broader Market: What Investors Need to Know

2025-07-15zacks.com

Merck Starts Phase III Studies on Once-Monthly Pill for HIV Prevention

2025-07-14businesswire.com

Merck to Initiate Phase 3 Trials for Investigational Once-Monthly HIV Prevention Pill

2025-07-11zacks.com

FDA Accepts Merck's Filing for Two-Drug, Once-Daily HIV Pill

2025-07-09zacks.com

Merck (MRK) Rises Higher Than Market: Key Facts

2025-07-09marketwatch.com

Merck dives into COPD treatments with $10 billion purchase of Verona Pharma

2025-07-09barrons.com

Verona Pharma Stock Jumps 21%. It's Being Bought for $10 Billion by Merck.

2025-07-09wsj.com

Merck to Buy Verona Pharma in $10 Billion Deal
More information for subscribed users:
detailed calculation of
Potential and Created Value,
website traffic data